GLP-1 / Metabolic

Survodutide Guide & Tableau de Dose

A dual GLP-1/glucagon agonist researched for weight and MASH.

Également appeléBI 456906

Voiesubcutaneous

Survodutide — Tableau de dose

Chaque ligne citée

Objectif	Dose	Fréquence	Durée	Preuve	Source
MASH with fibrosis (F1-F3) treatment - low dose	2.4 mg	1x/week	48 weeks (24-week dose escalation + 24-week maintenance)	Clinical	PMID 38847460
MASH with fibrosis (F1-F3) treatment - mid dose	4.8 mg	1x/week	48 weeks (24-week dose escalation + 24-week maintenance)	Clinical	PMID 38847460
MASH with fibrosis (F1-F3) treatment - high dose	6 mg	1x/week	48 weeks (24-week dose escalation + 24-week maintenance)	Clinical	PMID 38847460
Obesity/weight loss - low dose	0.6 mg	1x/week	46 weeks (20-week dose escalation + 26-week maintenance)	Clinical	PMID 38330987
Obesity/weight loss - dose 2	2.4 mg	1x/week	46 weeks (20-week dose escalation + 26-week maintenance)	Clinical	PMID 38330987
Obesity/weight loss - dose 3	3.6 mg	1x/week	46 weeks (20-week dose escalation + 26-week maintenance)	Clinical	PMID 38330987
Obesity/weight loss - high dose	4.8 mg	1x/week	46 weeks (20-week dose escalation + 26-week maintenance)	Clinical	PMID 38330987

À des fins de recherche et d'éducation uniquement. Pas un avis médical.

Survodutide FAQ

What is the typical Survodutide dosage?

In research, Survodutide has been studied at 2.4 mg 1x/week for MASH with fibrosis (F1-F3) treatment - low dose (48 weeks (24-week dose escalation + 24-week maintenance)). See the chart above for every studied protocol, each cited.

How do you reconstitute Survodutide?

Mix the lyophilized Survodutide with bacteriostatic water, then use the concentration to find your draw volume. The calculator on this page does the math for you.

Is Survodutide dosing backed by research?

Yes — every dose on this chart maps to a peer-reviewed source. Figures we cannot anchor to a study are left out. Survodutide is a research compound for laboratory use only.